Advertisement

Topics

Latest Collaborations in biotechnology NewsRSS

07:23 EDT 18th October 2017 | BioPortfolio

Vir Biotechnology Builds Pipeline, Capabilities, and Lays Out Strategy to Address Serious Infectious Diseases

-- Expands technology and global footprint with acquisition of Humabs BioMed SA -- Accesses clinical and preclinical stage assets from Alnylam, Visterra -- Total financing to date exceeds $500 million Vir Biotechnology, Inc. today announced agreements with Humabs BioMed SA, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALYN), and Visterra, In...

Visterra Announces Research Collaboration, Exclusive License, and Option Agreement for Infectious Diseases with Vir Biotechnology

Combines Visterra’s Proprietary Hierotope® Platform Technology and Vir Biotechnology’s Expertise in Innovative Research & Development for Infectious Diseases Vir to License up to Five Infectious Disease Research Programs from Visterra; has Option to a Minority Interest in VIS410 Visterra Received Upfront Payment, to Receive Fundi...

Alnylam and Vir Form Strategic Alliance to Advance RNAi Therapeutics for Infectious Diseases

– Agreement Includes Investigational RNAi Therapeutic Program for Hepatitis B Virus Infection and Discovery Collaboration on Additional Development Candidates for Treatment of Infectious Diseases – Alnylam

STAT Plus: CRISPR patent agreement seeks to expand use in crops

Two major powers in the use of CRISPR-Cas9 in agriculture have reached a surprising arrangement that could accelerate the creation of genome-edited crops.

Global Biomarker Partnering Terms and Agreements 20102017: Deal trends, players and financials [Report Updated: 01102017] Prices from USD $2995

The Global Biomarker Partnering Terms and Agreements 20102017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in biomarker partnering dealsBiomarker partnering agreement structureBiomarker partnering contract documentsTop biomark...

Protalix BioTherapeutics Enters into an Exclusive Ex-US Partnership with Chiesi Farmaceutici for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

Protalix grants Chiesi Ex-US rights to PRX-102, a chemically modified version of the recombinant protein alpha-Galactosidase-A protein Protalix to receive $25 million upfront, an additional up to $25 million in development costs and an additional up to $320 million in potential regulatory and commercial milestone payments Protalix to receive tiered royalties ranging from 15% to 35% on net sa...

Global Neuralgia Partnering 20102017 [Report Updated: 01102017] Prices from USD $1495

The Global Neuralgia Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. Trends in partnering deals Top deals by value Deals listed by company AZ, industry sector, stage of development, technology typeThe report provides understanding and access to the partnering deals and a...

Global Gastrointestinal Partnering 20102017: Deal trends, players and financials [Report Updated: 01102017] Prices from USD $2995

Global Gastrointestinal Partnering 2010 to 2017 provides the full collection of Gastrointestinal disease deals signed between the world's pharmaceutical and biotechnology companies since 2010. Trends in Gastrointestinal partnering dealsFinancial deal terms for headline, upfront and royalty by stage of developmentGastrointestinal partnering agreement structureGastrointestinal partnering contract do...

DuPont Pioneer and Danforth Plant Science Center Collaborate to Apply Cutting-edge Technologies to Improve Crops for Smallholder Farmers

The goal is to jointly develop improved food security crops. JOHNSTON, Iowa (PRWEB) October 17, 2017 DuPont Pioneer and the Donald Danforth Plant Science Center (Danforth Center) have entered into a multiyear public/private partnership, including licensing and research collaboration agreements. The goal is to jointly develop improved food security crops. Under the terms of the agreement, DuPont P...

Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2017 [Report Updated: 01102017] Prices from USD $2995

The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading companies. Comprehensive directory of personalized medicine in oncology deals since 2010Personalized medicine in oncology contract documentsPer...

TVR Communications' pCare™ Interactive Patient Systems and CBORD Partner To Improve The Patient Nutrition Experience

TVR Communications and CBORD® announce today an integrated dietary solution that pairs pCare™ Interactive Patient Systems, the multi-year recipient of the KLAS Category Leader rating (2015-2017 Best in KLAS: Software and Services Report), with CBORD’s leading healthcare nutrition solutions. New York, NY (PRWEB) October 17, 2017 TVR Communications and CBORD® announce today an integra...

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010 2017 [Report Updated: 01102017] Prices from USD $2995

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 20102017 report. The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multi...

Saniona AB: Saniona's Partner Cadent Therapeutics Receives Milestone from Novartis

PRESS RELEASE October 17, 2017 Saniona, a leading biotech company in the field of ion channels, today announced that its collaboration partner, Cadent Therapeutics (former Luc Therapeutics), has earned a milestone payment from Novartis for the initiation of a Phase 1 clinical study for one of its pipeline programs. "We wish to congratulate Cadent with this important milestone i...

Global Hypercholesterolemia Partnering 2010 to 2017 [Report Updated: 01102017] Prices from USD $1495

The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. Trends in partnering deals Top deals by value Deals listed by company AZ, industry sector, stage of development, technology typeThe report provides understanding and access to the partnering deals and agr...

OncLive® Adds George Washington Cancer Center to its Strategic Alliance Partnership Program

The partnership will support advancing cancer research and providing the latest information OncLive®, a leading digital provider of resources and information for oncology professionals announces the expansion of its Strategic Alliance Partnership (SAP) program with the addition of the George Washington Cancer Center (GW Cancer Center), announced Micha...

PrescribeWellness Partners with Clinical Support Services to Bring Comprehensive Patient Care to Healthcare Marketplace

PrescribeWellness and CSS Combine Face-to-Face and Phone-Based Medication Therapy Management Service Delivery Models to Offer an End-to-End Solution for Healthcare Payers PrescribeWellness, the cloud-based services company whose mission is to inspire collaboration for better health, today announced a partnership with Clinical Support Services (CSS) to ...

Scientist.com and VWR Collaborate to Create an End-to-End Online Research Solution

Scientist.com, the leading global online marketplace for research services, today announced its collaboration with VWR (NASDAQ: VWR), the leading global independent provider of product and service solutions to laboratory and production customers. VWR customers in the U.S. can now purchase thousands of custom products and research services through The VWR S...

Nativis Research Partner to Present at COGNO Conference in Australia

Promising Interim Data from First-in-Human Study in Australia using Nativis Voyager® System in Patients with Recurrent Glioblastoma (rGBM) SEATTLE (PRWEB) October 17, 2017 Nativis, Inc., a clinical stage life science, bio-electronics company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, today announced encouraging data supporting the us...

GenePeeks Expands Distribution to India with Exclusive Agreement with CORE Diagnostics

Global Adoption Continues for Company’s Advanced Analytics GenePeeks, Inc., a computational genomics company focused on transforming disease risk analysis, today announced an exclusive distribution agreement with

Verastem Pays Milestone Payment to Infinity Pharmaceuticals

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced payment of a $6 million milestone to Infinity Pharmaceuticals, Inc., representing the first milestone under the duvelisib license agreement between Verastem and Infinity. This milestone is based on the ac...

Acerus Announces Licensing of NATESTO® in South East Asian Countries

Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the signing of an agreement granting Eu Hwa Pte LTD. (“EU”) the exclusive right to market NATESTO® in Thailand, Malaysia/Brunei, Singapore, Vietnam, Philippines, Hong Kong/Macau and one other small South East Asian country. EU is a subsidiary of one of Taiwan’s largest pharmaceutical compa...

Cerevance Licenses Human Brain Tissue Profiling Technology from The Rockefeller University

Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has signed an agreement with The Rockefeller University to license a novel technology for profiling specific cell populations in human brain tissue. Cerevance is exercising an option agreement it previously signed with Rockefeller to license the technolog...

HSBlox Announces Strategic Partnership with Procivis to Create a Patient-Centered Smart Contract Solution for Healthcare Administration

HSBlox, a technology company bringing innovation and transparent economics to the healthcare ecosystem today announced a partnership with Swiss electronic identity specialist Procivis. Combining HSBlox’s Distributed Ledger Technology (DLT) smart contract solution for healthcare administration with Procivis’ advanced DLT authentication application will ...

IRB Collaborations With Tech Companies Could Mean What to the IRB?

Tech companies increasingly are partnering with research institutions. These partnerships include sharing data and project collaboration. What IRBs will want to know as this trend continues is what it means from a human research protection perspective.

CollPlant moves ahead on printing human organs

The company has announced a six-month agreement with "a leading medical instruments company" to develop a prototype biological implant.

Quick Search
Advertisement
 

review and buy Collaborations in biotechnology market research data and corporate reports here